Don't miss

Replay


LATEST SHOWS

FOCUS

How corruption has damaged Armenia's environment

Read more

THE INTERVIEW

'Changing FARC peace deal would be a huge historical error for Colombia'

Read more

TALKING EUROPE

EU ombudsman: 'Just raising an issue can be sufficient to change things'

Read more

TALKING EUROPE

Trouble in the eurozone: New Italian government puts pressure on establishment

Read more

IN THE PRESS

Celebrations after Mexico's win against Germany prompts 'fan-made' earthquake

Read more

YOU ARE HERE

France's Basque country, where singing is sacred

Read more

PERSPECTIVE

Charitable donations: 'By 2024, we believe giving will be the norm'

Read more

BUSINESS DAILY

Ex-Carrefour boss urged to give up €13 million retirement package

Read more

EYE ON AFRICA

Egypt, Morocco lose first World Cup matches after conceding last-minute goals

Read more

Sanofi-Aventis withdraws anti-obesity drug from European shelves

Text by AFP

Latest update : 2008-10-24

EU authorities have suspended sales of pharmaceutical giant Sanofi-Aventis' anti-obesity drug Acomplia across the continent, due to an abnormal risk of psychiatric problems.

EU authorities suspended sales of pharmaceutical giant Sanofi-Aventis' anti-obesity drug Acomplia across the continent Thursday, the firm announced, adding that it had not ruled out a worldwide halt.

"Sales have been halted in all the pharmacies in the 18 countries of the European Union where it is distributed," a company spokesman told AFP.

Sanofi-Aventis said the European Medicines Agency (EMEA) had warned that patients taking the drug ran almost double the normal risk of psychiatric problems.

"The risks of taking Acomplia are now greater than the benefits that the drug can bring the patient according to its current guidelines," the company said, citing the EMEA.

Europe has allowed sales of Acomplia since 2006, but it has not been authorised in the United States where authorities believe it encourages suicidal thoughts, even in patients with no history of depression.

The company said it had not ruled out withdrawing the drug in the 14 non-EU countries where it is sold. It said users of the drug should consult a doctor or pharmacist.
 

Date created : 2008-10-24

COMMENT(S)